{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:12:28Z","timestamp":1761743548020},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/cco.0b013e32834bb83f","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T23:56:09Z","timestamp":1317772569000},"page":"665-671","source":"Crossref","is-referenced-by-count":14,"title":["Advances in the understanding and management of primary myelofibrosis"],"prefix":"10.1097","volume":"23","author":[{"given":"Francisco","family":"Cervantes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-18-20210128","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"R2-18-20210128","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","article-title":"Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT).","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk Res"},{"key":"R3-18-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/MOH.0b013e328343998e","article-title":"Genetics of the myeloproliferative neoplasms.","volume":"18","author":"Abdel-Wahab","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"R4-18-20210128","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"R5-18-20210128","first-page":"53","article-title":"JAK2 inhibitors: whats the true potential Blood R","volume":"25","author":"Santos","year":"2011","journal-title":"ev"},{"key":"R6-18-20210128","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"key":"R7-18-20210128","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"R8-18-20210128","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"R9-18-20210128","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"R10-18-20210128","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"R11-18-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"R12-18-20210128","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers.","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"key":"R13-18-20210128","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"R14-18-20210128","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"key":"R15-18-20210128","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"key":"R16-18-20210128","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.","volume":"41","author":"Jones","year":"2009","journal-title":"Nat Genet"},{"key":"R17-18-20210128","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","article-title":"A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.","volume":"41","author":"Olcaydu","year":"2009","journal-title":"Nat Genet"},{"key":"R18-18-20210128","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms.","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat Genet"},{"key":"R19-18-20210128","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/leu.2009.225","article-title":"JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2461 haplotype is associated with inferior survival.","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"R20-18-20210128","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/leu.2010.126","article-title":"Frequency and clinical correlates of JAK2 461 (GGCC) haplotype in primary myelofibrosis.","volume":"24","author":"Guglielmelli","year":"2010","journal-title":"Leukemia"},{"key":"R21-18-20210128","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"R22-18-20210128","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors.","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"key":"R23-18-20210128","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.3324\/haematol.2010.025064","article-title":"Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked.","volume":"95","author":"Elliott","year":"2010","journal-title":"Haematologica"},{"key":"R24-18-20210128","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"R25-18-20210128","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"R26-18-20210128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2010.031831","article-title":"Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.","volume":"96","author":"Elena","year":"2010","journal-title":"Haematologica"},{"key":"R27-18-20210128","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"R28-18-20210128","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1182\/blood-2009-12-255943","article-title":"Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients.","volume":"115","author":"Morel","year":"2010","journal-title":"Blood"},{"key":"R29-18-20210128","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1182\/blood-2010-11-320002","article-title":"Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival.","volume":"117","author":"Vaidya","year":"2011","journal-title":"Blood"},{"key":"R30-18-20210128","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"R31-18-20210128","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"R32-18-20210128","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis.","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"},{"key":"R33-18-20210128","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood-2010-05-287417","article-title":"Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.","volume":"116","author":"Mesa","year":"2010","journal-title":"Blood"},{"key":"R34-18-20210128","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","article-title":"Pomalidomide is active in the treatment of anemia associated with myelofibrosis.","volume":"27","author":"Tefferi","year":"2009","journal-title":"J Clin Oncol"},{"key":"R35-18-20210128","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/leu.2010.254","article-title":"A phase-2 trial of low-dose pomalidomide in myelofibrosis with anemia.","volume":"25","author":"Begna","year":"2011","journal-title":"Leukemia"},{"key":"R36-18-20210128","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00277-010-1019-9","article-title":"Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.","volume":"89","author":"Martinez-Trillos","year":"2010","journal-title":"Ann Hematol"},{"key":"R37-18-20210128","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.","volume":"114","author":"Kroger","year":"2009","journal-title":"Blood"},{"key":"R38-18-20210128","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis.","volume":"16","author":"Karen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"R39-18-20210128","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2141.2010.08417.x","article-title":"Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).","volume":"152","author":"Robin","year":"2011","journal-title":"Br J Haematol"},{"key":"R41-18-20210128","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MOH.0b013e3283439964","article-title":"Targeting myeloproliferative neoplasms with JAK inhibitors.","volume":"18","author":"Pardanani","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"R42-18-20210128","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/leu.2010.269","article-title":"JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.","volume":"25","author":"Pardanani","year":"2011","journal-title":"Leukemia"},{"key":"R43-18-20210128","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"R44-18-20210128","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"key":"R45-18-20210128","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","article-title":"Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or postpolycythemia veraessential thrombocythemia myelofibrosis.","volume":"115","author":"Santos","year":"2010","journal-title":"Blood"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0b013e32834bb83f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:37:09Z","timestamp":1620949029000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201111000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32834bb83f","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}